Figure 2From: FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab FCGR2A response rates in patients with KRAS wild-type tumors. There was no significant difference in response rates when cetuximab was added to Nordic FLOX in the different FCGR2A subgroups (interaction P = 0.27).Back to article page